The Europe Live Biotherapeutic Products And Microbiome CDMO Market would witness market growth of 43.1% CAGR during the forecast period (2023-2029).
The fundamental tenet of the quickly developing discipline of microbiome therapeutics is utilizing the naturally developed medicinal capabilities of gut bacteria to produce desired clinical results/advantages. Furthermore, in recent years, the medical science field has been quite excited about the promising discoveries from microbiome-focused research, which provides a fresh viewpoint on personalized therapy. Given the active ingredients that are now being employed, this particular class of medications exists at the intersection of naturopathic treatments and clinically validated measures, having proven their capacity to provide real, quantifiable therapeutic effects.
The development of microbiome-based medicines for the treatment of a variety of ailments is reportedly being undertaken by many businesses, including public as well as private parties. The desire to collaborate with early-stage inventors in this field has also been shown by several significant pharmaceutical companies. Having said that, the majority of these projects are either in early-phase clinical trials or remain in the preclinical phases. Phase II/III trials are underway for several microbiome-based product candidates expected to fuel the market's expansion in the coming years.
LBPs do not now have a "separate status" inside the European legal system. Since live microorganisms—which are biological substances—are the active ingredients in LBPs, these drugs are, by definition, called biological, medical products. The legal and regulatory framework for biological and medical products must therefore be complied with by LBPs. According to recent data, inflammatory bowel illnesses [IBD] are still becoming more common and common across the region. Currently, IBD affects 0.2% of the population in Europe. With a focus on strict objective monitoring of the progression of the disease and a treat-to-target strategy in Europe, medical therapy, as well as disease management, have undergone tremendous change in recent decades with the aim of preventing early bowel disability and damage. Therefore, the rising need for the development of LBPs for treating IBD is responsible for the expansion of the regional market.
The Germany market dominated the Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022; thereby, achieving a market value of $5,950.7 Thousands by 2029. The UK market is registering a CAGR of 41.9% during (2023 - 2029). Additionally, The France market would showcase a CAGR of 44.2% during (2023 - 2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Live Biotherapeutic Products And Microbiome CDMO Market is Projected to reach USD 159.1 Million by 2029, at a CAGR of 42.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- C.difficile
- Crohns Disease
- IBS
- Diabetes
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 Europe Live Biotherapeutic Products And Microbiome CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 Europe C.difficile Market by Country
3.2 Europe Crohns Disease Market by Country
3.3 Europe IBS Market by Country
3.4 Europe Diabetes Market by Country
3.5 Europe Others Market by Country
Chapter 4. Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 UK Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 France Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 France Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 Russia Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.5 Spain Live Biotherapeutic Products And Microbiome CDMO Market
4.5.1 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.6 Italy Live Biotherapeutic Products And Microbiome CDMO Market
4.6.1 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.7 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market
4.7.1 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
TABLE 1 Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 2 Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 3 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 4 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 5 Europe C.difficile Market by Country, 2019 - 2022, USD Thousands
TABLE 6 Europe C.difficile Market by Country, 2023 - 2029, USD Thousands
TABLE 7 Europe Crohns Disease Market by Country, 2019 - 2022, USD Thousands
TABLE 8 Europe Crohns Disease Market by Country, 2023 - 2029, USD Thousands
TABLE 9 Europe IBS Market by Country, 2019 - 2022, USD Thousands
TABLE 10 Europe IBS Market by Country, 2023 - 2029, USD Thousands
TABLE 11 Europe Diabetes Market by Country, 2019 - 2022, USD Thousands
TABLE 12 Europe Diabetes Market by Country, 2023 - 2029, USD Thousands
TABLE 13 Europe Others Market by Country, 2019 - 2022, USD Thousands
TABLE 14 Europe Others Market by Country, 2023 - 2029, USD Thousands
TABLE 15 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
TABLE 16 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
TABLE 17 Germany Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 18 Germany Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 19 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 20 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 21 UK Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 22 UK Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 23 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 24 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 25 France Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 26 France Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 27 France Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 28 France Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 29 Russia Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 30 Russia Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 31 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 32 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 33 Spain Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 34 Spain Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 35 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 36 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 37 Italy Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 38 Italy Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 39 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 40 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 41 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 42 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 43 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 44 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 45 Key Information – Arranta Bio Holdings, LLC
TABLE 46 Key Information – Cerbios-Pharma SA
TABLE 47 Key Information – Biose Industrie
TABLE 48 Key Information – List Biological Laboratories, Inc.
TABLE 49 Key Information – AcuraBio Pty Ltd
TABLE 50 Key Information – Wacker Chemie AG
TABLE 51 Key Information – Quay Pharmaceuticals Ltd
TABLE 52 Key Information – BiomX, Inc.
TABLE 53 Key Information – Lonza Group AG
TABLE 54 Key Information – 4D Pharma Plc
List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2022
FIG 3 Europe Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2029
FIG 4 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2029, USD Thousands
FIG 5 Europe Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2022
FIG 6 Europe Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2029
FIG 7 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2029, USD Thousands